FrancophonIA/ELRC3.0 huggingface dataset:
English: In the case of accidental eye exposure, flush the eyes with plenty of water and seek medical attention.
Croatian: U slučaju slučajnog kontakta s očima, isprati s puno vode i potražiti liječničku pomoć.
English: Vomiting can be associated with serious, severely debilitating conditions and the cause should be investigated.
Croatian: Povraćanje može biti povezano s ozbiljnim, teškim iscrpljujućim stanjima te je zbog toga potrebno istražiti uzrok.
English: THE WORDS “FOR ANIMAL TREATMENT ONLY” For animal treatment only.
Croatian: RIJEČI „SAMO ZA PRIMJENU NA ŽIVOTINJAMA” Samo za primjenu na životinjama.
English: CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Veterinary medicinal product subject to prescription.
Croatian: UVJETI ILI OGRANIČENJA U POGLEDU OPSKRBE I PRIMJENE Veterinarsko-medicinski proizvod izdaje se na veterinarski recept.
English: People with known hypersensitivity to maropitant should administer the veterinary medicinal product with caution.
Croatian: Osobe preosjetljive na maropitant trebaju oprezno primjenjivati veterinarsko medicinski proizvod.
English: As maropitant is accumulated in the body during a 14 day treatment period due to metabolic saturation, careful monitoring of liver function and any adverse events should be implemented during long term treatment.
Croatian: Budući da se tijekom liječenja od 14 dana maropitant akumulira u tijelu zbog zasićenja metabolizma, kod dugotrajnog liječenja treba pažljivo pratiti funkciju jetre i pojavu bilo kojeg štetnog događaja.
English: As the pharmacokinetic variation is large and maropitant accumulates in the body after once daily repeated administration, lower doses than recommended might be sufficient in some individuals and when repeating the dose.
Croatian: S obzirom da je farmakokinetička varijacija velika i da se maropitant nakuplja u organizmu nakon ponovljene primjene jedanput dnevno, kod nekih jedinki doze niže od preporučenih mogu biti dovoljne, kada se primjena doze ponavlja.
English: Prevomax should be used with caution in animals suffering from or with predisposition for heart diseases.
Croatian: Prevomax treba upotrebljavati s oprezom u životinja koje boluju od srčane bolesti ili imaju predispozicije za tu bolest.
English: In laboratory studies, maropitant has been shown to be a potential eye irritant.
Croatian: U laboratorijskim ispitivanjima pokazalo se da maropitant može nadražiti oči.
English: • For the treatment and prevention of nausea induced by chemotherapy.
Croatian: • Za liječenje i sprječavanje mučnine prouzročene kemoterapijom.
English: By inhibiting the binding of substance P within the emetic centre, maropitant is effective against neural and humoral (central and peripheral) causes of vomiting.
Croatian: P u centru za povraćanje, maropitant učinkovito djeluje protiv neuralnih i humoralnih (centralnih i perifernih) uzroka povraćanja.
English: The elimination t1/2 following intravenous dosing was approximately 5.8 h.
Croatian: Poluvrijeme eliminacije t1/2 nakon intravenske primjene doze iznosilo je približno 5,8 sati.
English: For the major metabolite 10.4% of the maropitant dose was recovered in urine and 9.3% in faeces.
Croatian: Pretragom na glavni metabolit u urinu, nađeno je 10,4 % doze maropitanta i 9,3 % doze u fecesu.
English: To prevent vomiting, the veterinary medicinal product solution for injection should be administered more than 1 hour in advance.
Croatian: Za sprječavanje povraćanja, veterinarsko-medicinski proizvod, otopinu za injekciju treba davati više od 1 sat unaprijed.
English: Maropitant is metabolised in the liver and therefore should be used with caution in dogs and cats with liver disease.
Croatian: Maropitant se metabolizira u jetri pa je stoga potreban oprez kad se daje psima i mačkama s bolešću jetre.
English: MANUFACTURER RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturer responsible for batch release Produlab Pharma B.V.
Croatian: PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE U PROMET Naziv i adresa proizvođača odgovornog za puštanje serije u promet Produlab Pharma B.V.
English: The bioavailability of maropitant after subcutaneous administration in dogs was 90.7%.
Croatian: Bioraspoloživost maropitanta nakon supkutane primjene u pasa bila je 90,7 %.
English: QUANTITY OF THE ACTIVE SUBSTANCE(S) 10 mg/ml
Croatian: KOLIČINA DJELATNE(IH) TVARI 10 mg/ml
English: A variety of in vitro assays have demonstrated that maropitant binds selectively at the NK1 receptor with dose-dependent functional antagonism of substance P activity.
Croatian: Raznim vrstama in vitro ispitivanja dokazano je selektivno vezanje maropitanta za receptor NK1 s funkcionalnim antagonizmom prema aktivnosti tvari P, ovisnim o dozi.
English: CYP2D15 and CYP3A12 were identified as the canine isoforms involved in the hepatic biotransformation of maropitant.
Croatian: CYP2D15 i CYP3A12 identificirani su kao pseći izooblici uključeni u biotransformaciju maropitanta u jetri.
English: TARGET SPECIES Dogs, cats
Croatian: CILJNE VRSTE ŽIVOTINJA Psi, mačke
English: In cats, moderate to severe response to injection is very commonly observed (in approximately one third of cats).
Croatian: Kod mačaka se vrlo često (otprilike kod jedne trećine mačaka) javlja umjerena do teška reakcija na injekciju.
English: Plasma protein binding of maropitant in dogs is more than 99%.
Croatian: Vezanje maropitanta na proteine plazme iznosi kod pasa više od 99 %.
English: The responsible veterinarian should make a benefit-risk assessment before using the veterinary medicinal product in dogs less than 8 weeks of age, or in cats less than 16 weeks of age, or in pregnant or lactating bitches and cats.
Croatian: Nadležni veterinar mora procijeniti koristi i rizike prije primjene veterinarsko medicinskog proizvoda u pasa mlađih od 8 tjedana ili u mačaka mlađih od 16 tjedana ili u nosećih ili dojnih kuja i mačaka.
English: Due to the frequent occurrence of transient pain during subcutaneous injection, appropriate animal restraining measures may have to be applied.
Croatian: Zbog učestalog pojavljivanja prolazne boli prilikom supkutane injekcije, životinju će možda trebati sputati na odgovarajući način.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals, including isolated reports treated).
Croatian: Učestalost nuspojava određena je u skladu sa sljedećim pravilima: - vrlo česte (više od 1 na 10 tretiranih životinja pokazuju nuspojavu(e) - česte (više od 1 ali manje od 10 životinja na 100 tretiranih životinja) - manje česte (više od 1 ali manje od 10 životinja na 1.000 tretiranih životinja) - rijetke (više od 1 ali manje od 10 životinja na 10.000 tretiranih životinja) - vrlo rijetke (manje od 1 životinje na 10.000 tretiranih životinja, uključujući izolirane slučajeve).
English: Maropitant has been shown to be a potential eye irritant, and in the case of accidental eye exposure, flush the eyes with plenty of water and seek medical attention.
Croatian: Maropitant može nadražiti oči pa je u slučaju nehotičnog kontakta s očima potrebno isprati oči s puno vode i potražiti liječničku pomoć.
English: Use only according to the benefit-risk assessment by the responsible veterinarian.
Croatian: Primijeniti samo nakon procjene odnosa koristi i rizika nadležnog veterinara.
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Glass vial
Croatian: OSNOVNI PODACI KOJI SE MORAJU NALAZITI NA MALIM UNUTARNJIM PAKIRANJIMA
English: Shelf life after first opening the immediate packaging: 56 days.
Croatian: Rok valjanosti poslije prvog otvaranja unutarnjeg pakiranja: 56 dana.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE Outer carton
Croatian: PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU Kutija
English: The veterinary medicinal product should be used with caution in animals suffering from or with predisposition for cardiac diseases as maropitant has affinity to Ca- and K-ion channels.
Croatian: Veterinarsko-medicinski proizvod treba koristiti s oprezom kod jedinki koje imaju srčane bolesti ili onih koje imaju predispoziciju za te bolesti, jer maropitant ima afinitet prema kanalima iona kalcija i kalija.
English: MARKETING AUTHORISATION NUMBER(S) EU/2/17/211/001-004 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 19/06/2017
Croatian: BROJ(EVI) ODOBRENJA ZA STAVLJANJE U PROMET EU/2/17/211/001-004
English: The veterinary medicinal product should not be used concomitantly with Ca-channel antagonists as maropitant has affinity to Ca-channels.
Croatian: Veterinarsko-medicinski proizvod ne smije se davati istodobno s antagonistima kalcijevih kanala zbog afiniteta maropitanta prema kalcijevim kanalima.
English: Maropitant is highly bound to plasma proteins and may compete with other highly bound medicines.
Croatian: Maropitant se opsežno veže na proteine plazme te se može natjecati s drugim lijekovima koji imaju istu osobinu.
English: Products such as Prevomax should be used in conjunction with other supportive measures such as dietary control and fluid replacement therapy, as recommended by your veterinary surgeon.
Croatian: Proizvod kao Prevomax treba koristiti u kombinaciji s drugim potpornim mjerama, poput dijetne prehrane i nadoknade izgubljene tekućine, prema preporuci veterinara.
English: The volume of distribution at steady-state (Vss) was 2.3 l/kg and systemic clearance was 0.51 l/h/kg.
Croatian: Volumen distribucije u stabilnom stanju (Vss) bio je 2,3 l/kg, a sustavni klirens 0,51 l/h/kg.
English: The use of the veterinary medicinal product against vomiting due to motion sickness is not recommended.
Croatian: Ne preporučuje se upotreba veterinarsko-medicinskog proizvoda za sprječavanje povraćanja uzrokovanog bolešću kretanja.
English: • For the prevention of vomiting except that induced by motion sickness.
Croatian: • Za sprječavanje povraćanja osim onoga izazvanog bolešću kretanja.
English: Specific pharmacovigilance requirements: The PSURs for Prevomax shall be submitted at the same frequency as for Cerenia (reference product).
Croatian: PSUR-evi za Prevomax podnosit će se jednako često kao i za VMP Cerenia (referentni proizvod).
English: Plasma protein binding of maropitant in cats was estimated to be 99.1%.
Croatian: Procijenjeno je da vezanje maropitanta za proteine plazme iznosi u mačaka 99,1 %.
English: c/ Balmes 202, 6a 08006 Barcelona
Croatian: Dechra Veterinary Products S.L.U. c/ Balmes 202, 6a 08006 Barcelona
English: Renal clearance is a minor route of elimination, with less than 1% of a 1 mg/kg subcutaneous dose appearing in the urine as either maropitant or its major metabolite.
Croatian: Izlučivanje putem bubrega manje je značajan put eliminacije, pa se pri supkutanoj dozi od 1 mg/kg u urinu pojavi manje od 1 % maropitanta ili njegova glavnog metabolita.
English: Following repeated subcutaneous administration of once-daily doses of 1 mg/kg bodyweight for five consecutive days, accumulation was 146%.
Croatian: Nakon ponovljene supkutane primjene doza od 1 mg/kg tjelesne težine jednom dnevno tijekom pet uzastopnih dana, akumulacija je iznosila 146 %.
English: CYP1A and CYP3A-related enzymes were identified as the feline isoforms involved in the hepatic biotransformation of maropitant.
Croatian: Enzimi povezani s CYP1A i CYP3A identificirani su kao mačji izooblici uključeni u biotransformaciju maropitanta u jetri.
English: The use of Prevomax solution for injection against vomiting due to motion sickness is not recommended.
Croatian: Ne preporučuje se upotreba Prevomax otopine za injekciju za sprječavanje povraćanja uzrokovanog bolešću putovanja.
English: • For the prevention of vomiting and the reduction of nausea, except that induced by motion sickness.
Croatian: • Za sprječavanje povraćanja i smanjenje mučnine, osim kad je uzrok bolest kretanja.
English: The bioavailability of maropitant after subcutaneous administration in cats was 91.3%.
Croatian: Bioraspoloživost maropitanta nakon supkutane primjene u mačaka bila je 91,3 %.
English: Following a single intravenous dose at 1 mg/kg the initial plasma concentration was 363 ng/ml.
Croatian: Nakon jedne intravenske doze od 1 mg/kg, početna koncentracija u plazmi iznosila je 363 ng/ml.
English: To prevent vomiting, Prevomax solution for injection should be administered more than 1 hour in advance.
Croatian: Za sprječavanje povraćanja, Prevomax otopinu za injekciju treba davati 1 sat unaprijed.
English: Shelf life after first opening the vial: 56 days.
Croatian: Rok valjanosti poslije prvog otvaranja bočice: 56 dana.
English: The pharmacokinetic profile of maropitant when administered as a single subcutaneous dose of 1 mg/kg body weight to cats was characterised by a maximum concentration (Cmax) in plasma of approximately 165 ng/ml; this was achieved on average 0.32 hours (19 min) post-dosing (Tmax).
Croatian: Farmakokinetički profil maropitanta kada se primjenjuje u mačaka kao jednokratna supkutana doza od 1 mg/kg tjelesne težine karakterizira maksimalna koncentracija (Cmax) u plazmi od otprilike 165 ng/ml, a ta se koncentracija postigne u prosjeku za 0,32 sata (19 min) nakon primjene doze (Tmax).
English: Maropitant is metabolised in the liver and therefore should be used with caution in patients with hepatic disease.
Croatian: Maropitant se metabolizira u jetri pa je stoga potreban oprez kad se daje životinjama s bolešću jetre.
English: Dechra Veterinary Products Ltd. Sansaw Business Park Hadnall, Shrewsbury Shropshire SY4 4AS United Kingdom Tel.: +44 (0)1939 211200
Croatian: Sansaw Business Park Hadnall, Shrewsbury Shropshire SY4 4AS United Kingdom Tel.: +44 (0)1939 211200
English: The pharmacokinetic profile of maropitant when administered as a single subcutaneous dose of 1 mg/kg body weight to dogs was characterised by a maximum concentration (Cmax) in plasma of approximately 92 ng/ml; this was achieved within 0.75 hours post-dosing (Tmax).
Croatian: Farmakokinetički profil maropitanta, kada je primijenjen u pasa kao jednokratna supkutana doza od 1 mg/kg tjelesne težine, karakterizira maksimalna koncentracija (Cmax) u plazmi od otprilike 92 ng/ml, koja se postiže unutar 0,75 sati nakon primjene doze (Tmax).
English: STATEMENT OF ACTIVE SUBSTANCES 10 mg/ml maropitant
Croatian: SASTAV DJELATNIH TVARI 10 mg/ml maropitant
English: Peak concentrations were followed by a decline in systemic exposure with an apparent elimination half-life (t1/2) of 8.84 hours.
Croatian: Nakon maksimalnih koncentracija slijedilo je smanjenje sustavne izloženosti s prividnim poluvremenom eliminacije (t1/2) od 8,84 sata.
English: The efficacy of maropitant in reduction of nausea was demonstrated in studies using a model (xylazine-induced nausea).
Croatian: Djelotvornost maropitanta za smanjivanje mučnine dokazana je u ispitivanjima u kojima je korišten model (mučnina izazvana ksilazinom).
English: Peak concentrations were followed by a decline in systemic exposure with an apparent elimination half-life (t1/2) of 16.8 hours.
Croatian: Nakon maksimalnih koncentracija slijedilo je smanjenje sustavne izloženosti s prividnim poluvremenom eliminacije (t1/2) od 16,8 sata.
English: Following a single intravenous dose at 1 mg/kg the initial plasma concentration was 1040 ng/ml.
Croatian: Nakon jedne intravenske doze od 1 mg/kg, početna koncentracija u plazmi iznosila je 1040 ng/ml.
English: The volume of distribution at steady-state (Vss) was 9.3 l/kg and systemic clearance was 1.5 l/h/kg.
Croatian: Volumen distribucije u stabilnom stanju (Vss) bio je 9,3 l/kg, a sustavni klirens 1,5 l/h/kg.
English: Apart from transient reactions at the injection site following subcutaneous administration, maropitant was well tolerated in dogs and young cats injected daily with up to 5 mg/kg (5 times the recommended dose) for 15 consecutive days (3-times the recommended duration of administration).
Croatian: Osim prolaznih reakcija na mjestu supkutane primjene, psi i mlade mačke dobro podnose maropitant u dnevnoj dozi do 5 mg/kg (peterostruka preporučena doza) tijekom 15 uzastopnih dana (trostruka preporučena duljina trajanja primjene).
English: Renal and faecal clearances are minor routes of elimination for maropitant, with less than 1% of a 1 mg/kg subcutaneous dose appearing in the urine or faeces as maropitant.
Croatian: Izlučivanje putem bubrega i fecesa manje je značajan put eliminacije maropitanta pa se pri supkutanoj dozi od 1 mg/kg u urinu ili fecesu pojavi manje od 1 % maropitanta.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains:
Croatian: KVALITATIVNI I KVANTITATIVNI SASTAV 1 ml sadrži: Djelatna tvar: maropitant
English: Increases of approximately 10% in the QT interval of the ECG were observed in a study on healthy Beagle dogs administered 8 mg/kg orally; however, such an increase is unlikely to be of clinical significance.
Croatian: Povećanje QT intervala od otprilike 10 % zabilježeno je kod pretrage EKG-om, u ispitivanju provedenom na zdravim psima pasmine bigl, koji su primili peroralnu dozu od 8 mg/kg.
English: United Kingdom Dechra Veterinary Products Ltd. Sansaw Business Park Hadnall, Shrewsbury Shropshire SY4 4AS Tel.: +44 (0)1939 211200
Croatian: Sansaw Business Park Hadnall, Shrewsbury Shropshire SY4 4AS Tel.: +44 (0)1939 211200
English: The safety of maropitant has not been established in dogs less than 8 weeks of age, or in cats less than 16 weeks of age, or in pregnant or lactating dogs and cats.
Croatian: Neškodljivost maropitanta nije utvrđena kod pasa mlađih od 8 tjedana ili kod mačaka mlađih od 16 tjedana te kod gravidnih i dojnih kuja i mačaka.
English: Intravenous administration of the veterinary medicinal product should be given as a single bolus without mixing the product with any other fluids.
Croatian: Veterinarsko-medicinski proizvod treba intravenski primijeniti kao jednu bolus injekciju bez miješanja s bilo kakvim drugim tekućinama.
English: METHOD AND ROUTE(S) OF ADMINISTRATION SC, IV
Croatian: NAČIN I PUT(EVI) PRIMJENE s.c., i.v.
English: The safety of maropitant has not been established in dogs less than 8 weeks of age, or in cats less than 16 weeks of age, and in pregnant or lactating dogs and cats.
Croatian: Neškodljivost maropitanta nije utvrđena kod pasa mlađih od 8 tjedana i kod mačaka mlađih od 16 tjedana te kod gravidnih i dojnih kuja i mačaka.
English: Following repeated subcutaneous administration of once-daily doses of 1 mg/kg bodyweight for five consecutive days, accumulation was 250%.
Croatian: Nakon ponovljene supkutane primjene dozea od 1 mg/kg tjelesne težine, jednom dnevno, tijekom pet uzastopnih dana, akumulacija je iznosila 250 %.
English: The veterinary medicinal product solution for injection should be injected subcutaneously or intravenously, once daily, at a dose of 1 mg of maropitant / kg bodyweight (1 ml/10 kg bodyweight) for up to 5 consecutive days.
Croatian: Veterinarsko-medicinski proizvod, otopinu za injekciju treba primjenjivati supkutano ili intravenski jednom dnevno u dozi od 1 mg maropitanta po kg tjelesne težine (1 ml/10 kg tjelesne težine) do 5 uzastopnih dana.
English: Prevomax solution for injection should be injected subcutaneously or intravenously, once daily, at a dose of 1 mg of maropitant/kg body weight (1 ml/10 kg body weight).
Croatian: Prevomax otopinu za injekciju treba primjenjivati supkutano ili intravenski, jednom dnevno u dozi od 1 mg maropitanta / kg tjelesne težine (1 ml / 10 kg tjelesne težine) do 5 uzastopnih dana.
English: Dechra Veterinary Products S.L.U.
Croatian: Dechra Veterinary Products Ltd.
English: Pain at injection site may occur when injected subcutaneously.
Croatian: Prilikom supkutane primjene može se pojaviti bol na mjestu injiciranja.
English: Intravenous administration of Prevomax should be given as a single bolus without mixing the product with any other fluids.
Croatian: Intravenska primjena Prevomax treba biti u obliku jedne bolus injekcije bez miješanja s nekim drugim tekućinama.
English: Maropitant displays linear kinetics when administered subcutaneously within the 0.25-3 mg/kg dose range.
Croatian: Kada se daje supkutano, maropitant pokazuje linearnu kinetiku unutar raspona doze od 0,25-3 mg/kg.
English: Maropitant displays linear kinetics when administered subcutaneously within the 0.5-2 mg/kg dose range.
Croatian: Kada se daje supkutano, maropitant pokazuje linearnu kinetiku unutar raspona doze od 0,5-2 mg/kg.
English: STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) 1 ml contains:
Croatian: KVALITATIVNI I KVANTITATIVNI SASTAV DJELATNE(IH) TVARI I DRUGIH SASTOJAKA 1 ml sadrži: Djelatna tvar: maropitant
English: 5.2 Pharmacokinetic particulars
Croatian: Farmakokinetički podaci
English: WITHDRAWAL PERIOD(S)
Croatian: Razdoblje(a) karencije
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Prevomax 10 mg/ml injection maropitant
Croatian: Prevomax 10 mg/ml injekcija maropitant
English: Česká republika Sevaron ltd Palackeho trida 163 a 61200 Brno Tel. +420 541 426 370
Croatian: Palackeho trida 163 a 61200 Brno Tel.
English: ROUTE(S) OF ADMINISTRATION SC, IV
Croatian: PUT(EVI) PRIMJENE s.c., i.v.
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Prevomax 10 mg/ml solution for injection for dogs and cats
Croatian: NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Prevomax 10 mg/ml otopina za injekciju za pse i mačke
English: PACKAGE LEAFLET: Prevomax 10 mg/ml solution for injection for dogs and cats
Croatian: UPUTA O VMP-u: Prevomax 10 mg/ml otopina za injekciju za pse i mačke
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Prevomax 10 mg/ml solution for injection for dogs and cats maropitant
Croatian: NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Prevomax 10 mg/ml otopina za injekciju za pse i mačke maropitant
English: The elimination t1/2 following intravenous dosing was approximately 4.9 h. There appears to be an age-related effect on the pharmacokinetics of maropitant in cats with kittens having higher clearance than adults.
Croatian: Izgleda da je farmakokinetički učinak maropitanta povezan sa starošću mačaka jer je u mačića klirens veći nego u odraslih mačaka.
English: PHARMACEUTICAL FORM Solution for injection A clear, colourless to light yellow solution
Croatian: Bistra, bezbojna do svijetložuta otopina.
English: Maropitant
Croatian: NUSPOJAVE
English: Optimal treatment duration is not yet established.
Croatian: Do sada nije ustanovljeno optimalno trajanje liječenja.
English: There were no differences in response rates between the two dose groups.
Croatian: Nije bilo razlika u stopama odgovora između dvije dozirne skupine.
English: Longer duration of the treatment (> 36 months) may delay the onset of further recurrences; however the impact of this finding on the overall survival remains unknown.
Croatian: Duže trajanje liječenja (>36 mjeseci) može odgoditi pojavu dodatnih recidiva; međutim utjecaj tih nalaza na ukupno preživljenje ostaje nepoznat.
English: No conclusions can be drawn for other less common mutation subgroups due to the low number of observed events.
Croatian: Nikakav zaključak se ne može izvući za druge manje česte podskupine mutacija zbog malog broja opaženih događaja.
English: The safety database for children with Ph+ALL is very limited though no new safety
Croatian: Baza sigurnosnih podataka za djecu s Ph+ALL vrlo je ograničena iako nisu uočena nikakva nova sigurnosna pitanja.
English: Follow all your doctor's instructions carefully, even if they differ from the general information contained in
Croatian: Pažljivo slijedite sve upute dobivene od liječnika, čak i onda ako se razlikuju od općih informacija
English: The remaining circulating radioactivity consisted of a number of minor metabolites.
Croatian: Preostala se cirkulirajuća radioaktivnost sastojala od određenog broja manje važnih
English: Tumours were required to be measurable in at least one site of disease, and response characterisation based on Southwestern Oncology Group (SWOG) criteria.
Croatian: Za tumore je bilo potrebno da se mogu mjeriti na barem jednom mjestu bolesti, a karakterizacija odgovora bila je temeljena na kriterijima grupacije Southwestern Oncology Group (SWOG).